Total Payments
$131,300
2024 Payments
$10,562
Companies
18
Transactions
125
Medicare Patients
1,465
Medicare Billing
$252,355
Payment Breakdown by Category
Consulting$112,067 (85.4%)
Other$10,270 (7.8%)
Research$4,099 (3.1%)
Travel$2,729 (2.1%)
Food & Beverage$2,119 (1.6%)
Education$16.75 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $112,067 | 57 | 85.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,194 | 5 | 6.2% |
| Unspecified | $4,099 | 15 | 3.1% |
| Travel and Lodging | $2,729 | 15 | 2.1% |
| Food and Beverage | $2,119 | 31 | 1.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,076 | 1 | 1.6% |
| Education | $16.75 | 1 | 0.0% |
Payments by Type
General
$127,201
110 transactions
Research
$4,099
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $63,066 | 67 | $0 (2024) |
| Gilead Sciences, Inc. | $10,800 | 7 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $9,072 | 6 | $0 (2024) |
| Genentech USA, Inc. | $8,250 | 5 | $0 (2022) |
| Amgen Inc. | $6,786 | 11 | $0 (2018) |
| Jazz Pharmaceuticals Inc. | $6,450 | 5 | $0 (2020) |
| Celgene Corporation | $5,976 | 4 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $5,700 | 3 | $0 (2021) |
| PFIZER INC. | $4,250 | 2 | $0 (2021) |
| SERVIER PHARMACEUTICALS LLC | $3,740 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,562 | 6 | Rigel Pharmaceuticals, Inc. ($5,875) |
| 2023 | $15,068 | 13 | Gilead Sciences, Inc. ($5,700) |
| 2022 | $29,365 | 18 | ABBVIE INC. ($17,048) |
| 2021 | $26,126 | 13 | AbbVie Inc. ($13,200) |
| 2020 | $26,213 | 14 | AbbVie Inc. ($16,638) |
| 2019 | $2,568 | 10 | AbbVie, Inc. ($1,147) |
| 2018 | $21,049 | 48 | AbbVie, Inc. ($7,029) |
| 2017 | $350.01 | 3 | Pharmacyclics LLC, An AbbVie Company ($201.98) |
All Payment Transactions
125 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $149.71 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $52.51 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 03/19/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 02/20/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,687.50 | General |
| Category: ONCOLOGY | ||||||
| 01/26/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Consulting Fee | Cash or cash equivalent | $5,822.50 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 01/18/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 12/09/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $130.54 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $111.60 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $84.71 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/04/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 10/13/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 10/09/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Consulting Fee | Cash or cash equivalent | $1,027.50 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/05/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,384.00 | General |
| 05/02/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,687.50 | General |
| Category: ONCOLOGY | ||||||
| 04/12/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 03/06/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 03/01/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: ONCOLOGY | ||||||
| 02/10/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 01/23/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,687.50 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2022 | Janssen Scientific Affairs, LLC | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $72.57 | General |
| Category: Oncology | ||||||
| 12/10/2022 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $109.22 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2022 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $100.81 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2022 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 11/22/2022 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,935.00 | General |
| 11/22/2022 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,290.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| M14-546 | AbbVie, Inc. | $1,231 | 12 |
| A PHASE IBII MULTI-ARM STUDY WITH VENETOCLAX IN COMBINATION WITH COBIMETINIB AND VENETOCLAX IN COMBINATION WITH IDASANUTLIN IN PATIENTS AGED 60 YEARS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WHO ARE NOT ELIGIBLE FOR CYTOTOXIC THERAPY | F. Hoffmann-La Roche AG | $393.15 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 459 | 1,081 | $497,387 | $99,335 |
| 2022 | 9 | 347 | 573 | $295,343 | $52,081 |
| 2021 | 7 | 316 | 554 | $249,741 | $50,369 |
| 2020 | 9 | 343 | 621 | $234,436 | $50,570 |
Total Patients
1,465
Total Services
2,829
Medicare Billing
$252,355
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 58 | 372 | $145,452 | $36,505 | 25.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 133 | 257 | $179,643 | $29,069 | 16.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 39 | 187 | $52,502 | $12,314 | 23.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 66 | 66 | $56,232 | $9,575 | 17.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 68 | 96 | $9,984 | $2,473 | 24.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 17 | $12,735 | $2,454 | 19.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 17 | $9,397 | $1,837 | 19.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 17 | 20 | $10,040 | $1,404 | 14.0% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 20 | 22 | $14,542 | $1,383 | 9.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 16 | 16 | $2,576 | $1,268 | 49.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 11 | 11 | $4,284 | $1,054 | 24.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 100 | 158 | $108,028 | $18,456 | 17.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 126 | $47,632 | $10,719 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 94 | 142 | $68,548 | $10,226 | 14.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 50 | 50 | $41,452 | $7,285 | 17.6% |
| 99358 | Extended patient service without direct patient contact, first hour | Facility | 2022 | 23 | 24 | $11,240 | $2,149 | 19.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 17 | 17 | $2,639 | $1,269 | 48.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 17 | 30 | $3,120 | $788.16 | 25.3% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2022 | 12 | 12 | $7,932 | $635.34 | 8.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 14 | 14 | $4,752 | $554.00 | 11.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 95 | 132 | $76,655 | $15,344 | 20.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 20 | 163 | $53,436 | $14,007 | 26.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 92 | 123 | $54,294 | $9,641 | 17.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 46 | 46 | $35,722 | $6,975 | 19.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 28 | 43 | $13,606 | $2,374 | 17.4% |
About Brian Jonas, M.D., PHD
Brian Jonas, M.D., PHD is a Hematology & Oncology healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/23/2007. The National Provider Identifier (NPI) number assigned to this provider is 1558542209.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Brian Jonas, M.D., PHD has received a total of $131,300 in payments from pharmaceutical and medical device companies, with $10,562 received in 2024. These payments were reported across 125 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($112,067).
As a Medicare-enrolled provider, Jonas has provided services to 1,465 Medicare beneficiaries, totaling 2,829 services with total Medicare billing of $252,355. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Sacramento, CA
- Active Since 11/23/2007
- Last Updated 08/22/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1558542209
Products in Payments
- VENCLEXTA (Drug) $29,289
- VENCLEXTA (Biological) $10,211
- Rezlidhia (Drug) $9,042
- VYXEOS (Drug) $6,450
- Parsabiv (Biological) $6,169
- Venclexta (Drug) $4,872
- BESPONSA (Biological) $4,250
- Idhifa (Drug) $3,752
- TIBSOVO (Drug) $3,740
- ONUREG (Drug) $2,076
- Imbruvica (Drug) $451.86
- CC-486 (Drug) $148.03
- ADCETRIS (Biological) $100.14
- IMBRUVICA (Drug) $72.57
- Tavalisse (Drug) $29.79
- Blincyto (Biological) $21.14
- ELZONRIS (Drug) $16.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Sacramento
Dr. Joseph Tuscano, M.d, M.D
Hematology & Oncology — Payments: $633,262
Hematology & Oncology $633,262
Adam Giermasz, M.d., Phd, M.D., PHD
Hematology & Oncology — Payments: $518,605
Hematology & Oncology $518,605
Dr. David Gandara, M.d, M.D
Hematology & Oncology — Payments: $462,968
Hematology & Oncology $462,968
Dr. Scott Christensen, M.d, M.D
Hematology & Oncology — Payments: $391,606
Hematology & Oncology $391,606
Karen Kelly, M.d, M.D
Hematology & Oncology — Payments: $306,992
Hematology & Oncology $306,992
Paul Kaesberg, M.d, M.D
Hematology & Oncology — Payments: $221,939
Hematology & Oncology $221,939